Publicaciones en las que colabora con Pablo Sarobe Ugarriza (98)

2023

  1. Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies

    Frontiers in Immunology, Vol. 13

  2. Erratum: Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies(Front. Immunol., (2023), 13, (1044025), 10.3389/fimmu.2022.1044025)

    Frontiers in Immunology

  3. Mutated trimeric RBD vaccines: a platform against variants of concern

    Signal Transduction and Targeted Therapy

  4. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  5. Regulatory T Cell Inhibition by P60 Combined with Adenoviral AFP Transduced Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma

    Immunological Investigations, Vol. 52, Núm. 8, pp. 966-984

2022

  1. Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination

    Frontiers in Immunology, Vol. 13

  2. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer

    Frontiers in Immunology, Vol. 13

  3. TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity

    Cancer Letters, Vol. 528, pp. 45-58

2021

  1. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy

    Cancer Letters, Vol. 499, pp. 279-289

  2. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

  3. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes

    British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149

  4. The tgf-β pathway: A pharmacological target in hepatocellular carcinoma?

    Cancers, Vol. 13, Núm. 13

2020

  1. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens

    Journal for immunotherapy of cancer, Vol. 8, Núm. 1

  2. Cold‐inducible rna binding protein as a vaccination platform to enhance immunotherapeutic responses against hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 11, pp. 1-18

2019

  1. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model

    Cancer Immunology, Immunotherapy, Vol. 68, Núm. 3, pp. 379-393

  2. Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies

    Frontiers in Immunology, Vol. 10

  3. Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma

    Journal of Vascular and Interventional Radiology, Vol. 30, Núm. 7, pp. 1098-1105

2018

  1. Immunomodulatory properties of carvone inhalation and its effects on contextual fear memory in mice

    Frontiers in Immunology, Vol. 9, Núm. JAN

  2. The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer

    OncoImmunology, Vol. 7, Núm. 4

2017

  1. Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor

    Oncotarget, Vol. 8, Núm. 42, pp. 71709-71724